|
|
|
Volumn 81, Issue 13, 2001, Pages 773-775
|
|
Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ASPARAGINASE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
PREDNISOLONE;
VAP CYCLO PROTOCOL;
VAP-CYCLO PROTOCOL;
VINCRISTINE;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CHILD;
DISEASE COURSE;
FEMALE;
HUMAN;
MALE;
METHODOLOGY;
MIDDLE AGED;
MORTALITY;
MULTIMODALITY CANCER THERAPY;
NATURAL KILLER CELL;
NONHODGKIN LYMPHOMA;
NOSE TUMOR;
PATHOLOGY;
PROGNOSIS;
RADIOTHERAPY;
RETROSPECTIVE STUDY;
SURVIVAL RATE;
ADOLESCENT;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASPARAGINASE;
CHILD;
COMBINED MODALITY THERAPY;
CYCLOPHOSPHAMIDE;
DISEASE PROGRESSION;
DOXORUBICIN;
FEMALE;
HUMANS;
KILLER CELLS, NATURAL;
LYMPHATIC IRRADIATION;
LYMPHOMA, NON-HODGKIN;
MALE;
MIDDLE AGED;
NOSE NEOPLASMS;
PREDNISOLONE;
PROGNOSIS;
RETROSPECTIVE STUDIES;
SURVIVAL RATE;
VINCRISTINE;
|
|
EID: 0035838736
PISSN: 03762491
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (24)
|
|
References (0)
|
